Navigation Links
Protein shines light on cancer response
Date:2/24/2008

A technique that specifically tags tumors responding to chemotherapy may offer a new strategy for determining a cancer treatments effectiveness within days of starting treatment, according to a new study by Vanderbilt-Ingram Cancer Center investigators.

Appearing online ahead of print in Nature Medicine, the researchers report the identification of a small protein that specifically recognizes tumors responding to chemotherapy. They show that the protein, when tagged with a light-emitting molecule, can be used to visualize cancer response in mice just two days after starting therapy.

Improved monitoring of tumor response could help customize patient treatment and also speed up the development of new cancer drugs, said senior investigator Dennis Hallahan, M.D., the Ingram Professor of Cancer Research and chair of Radiation Oncology at Vanderbilt University Medical Center.

Currently, response to chemotherapy is determined by measuring changes in tumor size with imaging techniques like CT (computed tomography) and MRI (magnetic resonance imaging).

It takes two to three months of cancer therapy before we can determine whether the therapy has been effective for a patient, he said. If we can get that answer within one to two days, we can switch that patient to an alternative regimen very quickly.

Rapid assessment of tumor response is especially important now, Hallahan says, given recent advances in molecular targeted therapies chemotherapy medications that specifically interfere with the growth and proliferation of cancer cells while avoiding damage to healthy cells.

We now have so many molecular targeted drugs to choose from, and that number is growing every year, so we are now at a point where a patient can be switched from one regimen to another, he said. But we need the tools to make the decision to use an alternative therapy with the patient.

To find a rapid and noninvasive method to assess cancer response to these therapies, Hallahan focused not on tumor size, but molecular and cellular changes in responding tumors.

From a panel of billions of protein fragments, or peptides, Hallahan and colleagues identified one that specifically bound to tumors responding to therapy. To this peptide, they attached a light-emitting molecule and injected these labeled peptides into mice that had been implanted with human tumors.

Using specialized imaging cameras that detect light in the near-infrared range (invisible to the human eye), the investigators saw that tumors responding to therapy were brighter than non-responding tumors. The peptide detected response in a wide range of tumors brain, lung, colon, prostate and breast within two days of initiation of treatment.

The key word here is days, Hallahan said. This will allow us to minimize the duration of treatments with ineffective regimens in cancer patients.

The next step will be to move the technology into humans. The imaging technique used in mice (near-infrared) is not sensitive enough to penetrate deeply into human tissues, so the researchers are adapting the technology to an imaging modality commonly used in humans, called PET (positron emission tomography).

This imaging peptide will enter clinical trials within about 18 months, Hallahan said. The purpose, when we bring it into people, is to ask a very simple question: can we image responding cancers in people as well as we can in mice?

If so, he says that he suspects that such molecular imaging methods could help accelerate the development of new chemotherapeutic drugs.

In the pharmaceutical industry, well have a patient on a drug for months before we can re-evaluate the size of the tumor, Hallahan said. If we can get that answer within a couple of days, it will speed cancer drug development in the early phases of clinical trials.


'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. 3 newly discovered ERK pathway proteins related to CagA induced disease
2. U of M researchers determine structure of protein that mutates DNA of the AIDS virus HIV-1
3. Oncoproteins double-team and destroy vital tumor-suppressor
4. Lack of Brain Protein May Explain Rain Man Abilities
5. Discovery of overdrive protein could broaden drug design options
6. Burn Fat with fucoPROTEIN(TM) Bars
7. Unsuspected protein determines resistance to breast cancer treatment
8. Breaking down Huntingtons disease one protein at a time
9. New findings show Enbrel significantly reduced levels of C-reactive protein
10. Protein Linked With Poor Prognosis in Early-Stage Breast Cancer
11. Deafness and seizures result when mysterious protein deleted in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: